ImmunoPrecise Antibodies Ltd. (IPA) Financials

$0.45

south_east
-$0.07 (-13.63%)
Day's range
$0.43
Day's range
$0.52

IPA Income statement / Annual

Last year (2024), ImmunoPrecise Antibodies Ltd.'s total revenue was $24.52 M, an increase of 18.65% from the previous year. In 2024, ImmunoPrecise Antibodies Ltd.'s net income was -$27.18 M. See ImmunoPrecise Antibodies Ltd.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 04/30/2024 04/30/2023 04/30/2022 04/30/2021 04/30/2020 04/30/2019 04/30/2018 04/30/2017 04/30/2016 12/31/2014
Operating Revenue $24.52 M $20.67 M $19.36 M $17.91 M $14.06 M $10.93 M $5.44 M $2.63 M $1.90 M $1.76 M
Cost of Revenue $12.47 M $9.10 M $8.38 M $6.37 M $6.02 M $5.63 M $2.99 M $1.21 M $298,319.00 $265,333.00
Gross Profit $12.05 M $11.56 M $10.98 M $11.54 M $8.03 M $5.29 M $2.45 M $1.42 M $1.60 M $1.50 M
Gross Profit Ratio 0.49 0.56 0.57 0.64 0.57 0.48 0.45 0.54 0.84 0.85
Research and Development Expenses $4.04 M $12.28 M $6.69 M $1.97 M $446,280.00 $485,845.00 $509,248.00 $660,408.00 $302,769.00 $621,639.00
General & Administrative Expenses $15.59 M $19.81 M $16.97 M $12.65 M $7.95 M $7.65 M $6.31 M $6.70 M $997,291.00 $64,835.00
Selling & Marketing Expenses $3.54 M $3.61 M $740,000.00 $691,000.00 $377,728.00 $819,250.00 $134,680.00 $119,192.00 $20,830.00 $6,693.00
Selling, General & Administrative Expenses $19.14 M $23.42 M $17.71 M $13.34 M $8.33 M $8.47 M $6.45 M $6.82 M $1.02 M $64,835.00
Other Expenses -$11.13 M $0.00 $2.75 M $132,000.00 $2.65 M $1.91 M $256,519.00 $376,776.00 $340,317.00 $1,040.00
Operating Expenses $12.05 M $39.78 M $27.15 M $15.71 M $12.08 M $11.52 M $7.21 M $7.84 M $1.66 M $65,875.00
Cost And Expenses $24.52 M $48.88 M $35.53 M $22.09 M $18.10 M $17.15 M $10.20 M $7.84 M $1.66 M $65,875.00
Interest Income $23,000.00 $270,000.00 $279,000.00 $282,000.00 $272,006.00 $30,085.00 $73,004.00 $0.00 $9,308.00 $0.00
Interest Expense $19,000.00 $30,000.00 $419,000.00 $863,000.00 $1.44 M $1.32 M $50,591.00 $16,216.00 $9,308.00 $338.00
Depreciation & Amortization $5.74 M $6.69 M $3.77 M $3.71 M $3.41 M $2.26 M $458,079.00 $50,609.00 $41,881.00 $1,040.00
EBITDA -$22.95 M -$21.04 M -$11.99 M -$1.42 M -$449,000.00 -$4.03 M -$4.32 M -$5.40 M $293,835.00 $368,573.00
EBITDA Ratio -0.94 -1.03 -0.63 -0.01 -0.03 -0.36 -0.82 -1.96 0.15 -0.04
Operating Income Ratio -0.56 -1.26 -0.81 -0.37 -0.29 -0.57 -0.91 -0.53 0.13 -0.02
Total Other Income/Expenses Net -$14.94 M -$2.14 M -$67,000.00 -$2.08 M -$1.47 M -$1.09 M -$517,849.00 -$4.08 M $221,182.00 -$25,100.00
Income Before Tax -$28.70 M -$27.75 M -$15.85 M -$6.00 M -$5.29 M -$7.61 M -$5.06 M -$5.47 M $242,646.00 -$62,313.00
Income Before Tax Ratio -1.17 -1.34 -0.82 -0.33 -0.38 -0.7 -0.93 -2.08 0.13 -0.04
Income Tax Expense -$1.53 M -$1.19 M $861,000.00 $1.35 M -$345,728.00 $4,788.00 $109,715.00 -$82,378.00 $91,611.00 $338.00
Net Income -$27.18 M -$26.56 M -$16.71 M -$7.34 M -$4.95 M -$7.62 M -$5.17 M -$5.38 M $151,035.00 -$62,313.00
Net Income Ratio -1.11 -1.29 -0.86 -0.41 -0.35 -0.7 -0.95 -2.05 0.08 -0.04
EPS -1.06 -1.07 -0.85 -0.45 -0.36 -0.61 -0.57 -1.36 0.1 -0.11
EPS Diluted -1.06 -1.07 -0.85 -0.45 -0.36 -0.61 -0.57 -1.36 0.1 -0.11
Weighted Average Shares Out $25.64 M $24.90 M $19.69 M $16.47 M $13.63 M $12.54 M $9.11 M $3.96 M $1.92 M $550,129.00
Weighted Average Shares Out Diluted $25.64 M $24.90 M $19.69 M $16.47 M $13.63 M $12.54 M $9.11 M $3.96 M $1.92 M $550,129.00
Link